^
Association details:
| Biomarker: | FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) + daunorubicin (Topoisomerase II inhibitor, DNA intercalator) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
AML:…after standard-dose cytarabine induction...standard-dose cytarabine with daunorubicin and oral midostaurin...(FLT3 mutated [ITD or TKD]
